Form 4: Lilly Endowment Inc. Sells Over 179,000 Shares of Eli Lilly & Co.

Lilly Endowment Inc. sold over 179,000 shares of Eli Lilly & Co. common stock in multiple transactions on June 6, 2024.

Summary

• Lilly Endowment Inc. sold a total of 179,617 shares of Eli Lilly & Co. common stock on June 6, 2024.
• The sales were executed in multiple transactions throughout the day.
• The prices per share ranged from $836.151 to $846.336.
• The sales resulted in a decrease in Lilly Endowment Inc.'s holdings to 98,008,810 shares.
• The transactions were reported on a Form 4 filing with the SEC.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale, with no inherent positive or negative sentiment. It is a routine regulatory filing.

Industry Context

Form 4 filings are a standard part of regulatory compliance for significant shareholders and provide transparency into their trading activities. This filing indicates a reduction in Lilly Endowment Inc.'s holdings in Eli Lilly & Co.

Comparison to Industry Standards

• Form 4 filings are a common practice for major shareholders in publicly traded companies, such as Berkshire Hathaway's filings for their holdings in Apple or other companies.
• The level of detail provided in this Form 4 is consistent with standard SEC requirements for reporting insider transactions.
• The multiple transactions at varying prices are typical for large block trades, similar to what might be seen with institutional investors like Vanguard or BlackRock.

Stakeholder Impact

• The sale of shares by a major shareholder like Lilly Endowment Inc. could potentially have a minor impact on the stock price of Eli Lilly & Co., but the effect is likely to be minimal given the large number of shares outstanding.

Key Dates

Keywords

Lilly Endowment Inc., Eli Lilly & Co., stock sale, Form 4, share transaction, beneficial ownership